Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in ...

(Courtesy of Texas Children's Hospital) At Texas Children's Hospital, Fivecoat's daughter Shelly McAfee and her husband Tyler ...

Veteran NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year, the National Basketball Referees ...

NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year and is in treatment, the National ...

In August, Syros discontinued enrollment in the Phase II SELECT-AML-1 trial, in which it was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine in newly diagnosed, unfit ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

I was diagnosed with acute myeloid leukemia, and the prognosis was not good. I was given just a few months to live. The only ...

The response rate in the control cohort is in line with historical data on azacitidine. Investors, already burnt by setbacks ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...